Rafael Grochot, Medical Oncologist – Clinical Trial Specialist at Sarah Cannon Research Institute, shared a post on LinkedIn about a paper he co-authored with colleagues published in JCO Precision Oncology:
“Proud of our work on safety and activity of FGFR inhibitors in early phase clinical trials published today on American Society of Clinical Oncology (ASCO) JCO Precision Oncology, JCO Journals.”
Authors: Rafael Grochot, Kroopa Joshi, Antonella Cammarota, Rachel Woodford, Gethini Sathanantham, Anja Williams, Tobias Arkenau, Vivek Subbiah, Charles Swanton, Elisa Fontana.
More posts featuring Rafael Grochot.